The p53 pathway and its inactivation in neuroblastoma.

@article{Tweddle2003ThePP,
  title={The p53 pathway and its inactivation in neuroblastoma.},
  author={Deborah A Tweddle and Andrew D. J. Pearson and Michelle Haber and Murray D Norris and Chengyuan Xue and Claudia L. Flemming and John Lunec},
  journal={Cancer letters},
  year={2003},
  volume={197 1-2},
  pages={
          93-8
        }
}
Early studies of p53 in neuroblastoma reported infrequent mutations in tumours and cell lines. Cytoplasmic sequestration was later proposed as an alternative mechanism of inactivation, but many studies have since reported an intact p53 pathway in neuroblastoma cell lines, as detected by nuclear p53 accumulation after DNA damage, intact DNA binding, transcriptional activation of target genes and the induction of apoptosis. In some MYCN amplified cell lines however, an irradiation induced G(1… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 85 CITATIONS

Preclinical pharmacology of the MDM2 antagonist nutlin-3a

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Novel experimental targeted therapy of neuroblastoma

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

3 The Cell Biology of Neuroblastoma

VIEW 1 EXCERPT
CITES BACKGROUND

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2004
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 7 Citations per year over the last 3 years

Similar Papers

Loading similar papers…